Prosecution Insights
Prosecution Insights
19 pending office actions • 9 art units • 15 examiners • 1 of 19 (5%) have an AI response strategy ready • 33 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (5%) |
| §103 only | 3 (16%) |
| §112 only | 6 (32%) |
| Double-patenting only | 1 (5%) |
| Double-patenting + other | 3 (16%) |
| Multi-statute (no §101) | 4 (21%) |
| No statute on record | 1 (5%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHAO, ALLEN | 4 | 66.7% | +0.0% |
| DAHLE, CHUN WU | 2 | 49.8% | +51.4% |
| SHTERENGARTS, SAMANTHA L | 1 | 79.3% | +8.0% |
| AULAKH, CHARANJIT | 1 | 80.8% | -15.2% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.3% |
| SEAMAN, D MARGARET M | 1 | 76.6% | +8.0% |
| WEDDINGTON, KEVIN E | 1 | 75.2% | +10.1% |
| REDDIG, PETER J | 1 | 58.1% | +39.9% |
| ALSOMAIRY, SARAH ABDOALATIF | 1 | 59.4% | +26.5% |
| BELL, SARA ELIZABETH | 1 | 69.1% | +38.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18678931 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | AULAKH, CHARANJIT | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18330141 | COMBINATION THERAPY OF ANTI-PD-1 ACTIVE AGENT, ANTI-TIM-3 ACTIVE AGENT, AND ANTI-LAG-3 ACTIVE AGENT FOR TREATING CANCER | ALSOMAIRY, SARAH ABDOALATIF | 28d overdue |
| 18581959 | COMBINATIONS AND USES THEREOF | DAHLE, CHUN WU | — |
| 18411350 | COMBINATIONS AND USES THEREOF | DAHLE, CHUN WU | — |
| 18245019 | TOPICAL TREATMENT OF VITILIGO | SOROUSH, LAYLA | — |
| 17541627 | ANTI-CD19 COMBINATION THERAPY | MIDDLETON, DANAYA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18330141 | COMBINATION THERAPY OF ANTI-PD-1 ACTIVE AGENT, ANTI-TIM-3 ACTIVE AGENT, AND ANTI-LAG-3 ACTIVE AGENT FOR TREATING CANCER | ALSOMAIRY, SARAH ABDOALATIF | 28d overdue |
| 18192313 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | BELL, SARA ELIZABETH | 6d |
| 18373648 | ANTI-PD-1/LAG-3 BISPECIFIC ANTIBODIES AND USES THEREOF | REDDIG, PETER J | 27d |
| 18671477 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | CHANDRAKUMAR, NIZAL S | — |
| 18581959 | COMBINATIONS AND USES THEREOF | DAHLE, CHUN WU | — |
| 18411350 | COMBINATIONS AND USES THEREOF | DAHLE, CHUN WU | — |
| 18496540 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D AND RELATED PRODUCTS AND METHODS | WEDDINGTON, KEVIN E | — |
| Art Unit | Apps |
|---|---|
| 1622 | 5 |
| 1625 | 3 |
| 1646 | 2 |
| 1621 | 1 |
| 1629 | 1 |
| 1699 | 1 |
| 1623 | 1 |
| 1674 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18777124 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | SHTERENGARTS, SAMANTHA L | — | DP | Non-Final OA | — | Pending | Jul 18, 2024 |
| 18678931 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | AULAKH, CHARANJIT | 1621 | §112DP | Non-Final OA | — | Pending | May 30, 2024 |
| 18671477 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | CHANDRAKUMAR, NIZAL S | 1625 | §103Other | Non-Final OA | — | Pending | May 22, 2024 |
| 18639041 | 2-AZABICYCLO[2.2.1]HEPTANE KRAS INHIBITORS | SEAMAN, D MARGARET M | 1625 | §103§112DP | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18602434 | Bicyclic Ureas As Kinase Inhibitors | CHAO, ALLEN | 1622 | §112 | Non-Final OA | — | Pending | Mar 12, 2024 |
| 18584553 | Heterocyclic Compounds As Kinase Inhibitors | CHAO, ALLEN | 1622 | §112 | Non-Final OA | — | Pending | Feb 22, 2024 |
| 18581959 | COMBINATIONS AND USES THEREOF | DAHLE, CHUN WU | — | §103§112 | Non-Final OA | — | Pending | Feb 20, 2024 |
| 18411350 | COMBINATIONS AND USES THEREOF | DAHLE, CHUN WU | — | §103§112 | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18512514 | Heteroaryl Fluoroalkenes As DGK Inhibitors | CHAO, ALLEN | 1622 | §112 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18512625 | Heteroaryl Fluoroalkenes As DGK Inhibitors | CHAO, ALLEN | 1622 | §112 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18496540 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D AND RELATED PRODUCTS AND METHODS | WEDDINGTON, KEVIN E | 1629 | §112 | Non-Final OA | — | Pending | Oct 27, 2023 |
| 18373648 | ANTI-PD-1/LAG-3 BISPECIFIC ANTIBODIES AND USES THEREOF | REDDIG, PETER J | 1646 | §103Other | Non-Final OA | 27d | Pending | Sep 27, 2023 |
| 18330141 | COMBINATION THERAPY OF ANTI-PD-1 ACTIVE AGENT, ANTI-TIM-3 ACTIVE AGENT, AND ANTI-LAG-3 ACTIVE AGENT FOR TREATING CANCER | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §101§102§103§112 | Non-Final OA | 28d overdue | AI Ready | Jun 06, 2023 |
| 18192313 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | BELL, SARA ELIZABETH | 1625 | §112Other | Non-Final OA | 6d | Pending | Mar 29, 2023 |
| 18245019 | TOPICAL TREATMENT OF VITILIGO | SOROUSH, LAYLA | 1622 | §102§103§112 | Final Rejection | — | Pending | Mar 13, 2023 |
| 18092610 | PD-L1/STING CONJUGATES AND METHODS OF USE | JARRELL, NOBLE E | 1699 | Other | Non-Final OA | 51d overdue | Pending | Jan 03, 2023 |
| 17991482 | COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR | VALLE, ERNESTO | 1623 | §103 | Final Rejection | 7d | Pending | Nov 21, 2022 |
| 17541627 | ANTI-CD19 COMBINATION THERAPY | MIDDLETON, DANAYA L | 1674 | §103§112Other | Non-Final OA | — | Pending | Dec 03, 2021 |
| 16791561 | CYCLIN-DEPENDENT KINASE 2 BIOMARKERS AND USES THEREOF | KATAKAM, SUDHAKAR | 1658 | §103DP | Final Rejection | — | Pending | Feb 14, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial